Asst. Prof. @cityofhope | Cancer systems biology | Precision oncology | views=own
Los Angeles, CA
Joined October 2016
- Tweets100
- Following162
- Followers99
- Likes160
New study from our lab explores ONC201 as potential add-on treatment for everolimus-resistant breast cancer
This Post is from an account that no longer exists. Learn more
6
257
It was such a pleasure presenting my research on breast cancer precision oncology at NCI!
This Post is from an account that no longer exists. Learn more
Aritro Nath, Ph.D. retweeted
In our latest research, we model how CDK4/6 inhibitor resistant breast cancer cells facilitate growth of sensitive cells, allowing them to evade therapy. Out now in Nature Communications!
@dendroicap
rdcu.be/dfFL7
We are looking to hire a senior staff scientist w/ experience in single cell genomics and machine learning. Please reach out and share with colleagues!
Join us as a Staff #Scientist - Translational Bioinformatics and be a part of the collaborative research in Bild and Nath labs focusing on translational cancer systems biology. Apply today! cityofhopejobs.org/job/staff…
#phdpositions #CancerResearch #researchjobs #sciencejobs #oncology
Aritro Nath, Ph.D. retweeted
Just published in @eLife: our review of adaptive therapy math models:
elifesciences.org/articles/8…
A collaboration of 12 scientists mapping out how to bridge mathematics and clinical translation.
🧵🧵🧵
Aritro Nath, Ph.D. retweeted
Happy to update that the single-cell RNA-Seq based drug repurposing prediction tool, ASGARD, is published by @NatureComms !
The tool gives personalized prediction and ranking of drugs.
Work is led by Dr. Bing He, one of the best postdocs I've worked with.
nature.com/articles/s41467-0…
Filtering scRNA-seq data based on arbitrary UMI thresholds can lead to loss of cells with low expression. We tackle this problem of threshold optimation in our latest work.
Great job @IsaacB76404445, congrats on your first paper!
New Research: A machine learning framework for scRNA-seq UMI threshold optimization and accurate classification of cell types: Recent advances in single cell RNA sequencing (scRNA-seq) technologies have been invaluable in the study of the… frontiersin.org/articles/10.… #Genetics
Everolimus (mTOR inhibitor) can benefit patients with advanced ER+ breast cancer. Our latest predictive model uses cancer cell gene expression to predict clinical response to everolimus:
frontiersin.org/articles/10.…
3
Preview of the fantastic application of archetype analysis by @sarahmgroves @quarantalab to characterize phenotypic plasticity of small cell lung cancer
authors.elsevier.com/a/1fnvg…
1
What a crazy week this was!!!Submitted my first two senior author papers.. both on the same day. But made it back by 5 to spend time with family each day
#AcademicChatter
Aritro Nath, Ph.D. retweeted
ENDORSE: an expression signature-based prognostic model that can predict response to endocrine therapy in ER+ #breastcancer --> https://xitter.gq/t.co/js5hVUhAkv
@AndreaBildLab @aritromics @cityofhope #biomarker
I am excited to share that ENDORSE: a prognostic model for endocrine therapy in early and advanced ER+ breast cancers is out now in Molecular Systems Biology!!! @MolSystBiol
embopress.org/doi/full/10.15…
Unsolicited requests from predatory journals are annoying... but sometimes they are hilarious 🤣😆
1
3
Aritro Nath, Ph.D. retweeted
The paper describing our software tool, MadHitter github.com/ruppinlab/madhitt…, to identify combinatorial receptor-mediated treatments from scRNA-seq of tumors has been published in @NatureComms. nature.com/articles/s41467-0… 1/
Aritro Nath, Ph.D. retweeted
Finally, my work is out in Genes to Cells!
Our findings provide a rationale for targeting miR-215 as a therapeutic intervention for inflammatory conditions in the SI onlinelibrary.wiley.com/doi/…
Aritro Nath, Ph.D. retweeted
Announcing our intent to acquire @CancerCenter.
With Cancer Treatment Centers of America, City of Hope builds on and accelerates its vision to forge partnerships and find new avenues for its expertise to positively impact as many lives as possible. #cancercare #cancerresearch
Most metastatic ER+ breast cancers are treated with hormone therapy until progression. Our latest preprint presents a prognostic model that can identify patients who will likely not benefit from hormone therapy as first-line treatment.
medrxiv.org/content/10.1101/…
